613 results about "Melanoma" patented technology

The invention relates to application of a tea exosome in preparation of a medicine for improving skin pigmentation, the tea exosome is creatively extracted and purified, and the tea exosome can effectively inhibit proliferation of melanoma cells and inhibit expression of melanin generation related protein by scavenging free radicals and inhibiting tyrosinase activity, so that the effect of improving skin pigmentation is achieved. The intracellular melanin removal is promoted. In a mouse in-vivo experiment, after the tea exosome is applied, it is observed that the skin epidermis thickness of a mouse is reduced, the dermis thickness is increased, collagen arrangement is tighter and more ordered, the content is increased, and meanwhile generation of inflammatory factors is reduced. The tea exosome can significantly increase the content of a melanin autophagy key factor LC3B and reduce the content of P62 to promote melanin autophagy, and has good percutaneous infiltration capacity, thereby playing a role in improving skin pigmentation.

The invention provides a coordination nano assembly of chiral cyclopeptide and manganese ions as well as a preparation method and application of the coordination nano assembly. According to the method, a manganese superoxide dismutase protein structural domain and a unique tumor microenvironment of melanoma high tyrosinase are combined, and polypeptide sequences L-YD-hL-DD-h, L-YL-HL-DL-H and D-yD-hD-dD-h with different chirality are designed for the first time; the chirality of the polypeptide is regulated and controlled, the in-vivo circulation stability and the cell entry efficiency of the nano assembly are improved, the coordination self-assembly of manganese and different chiral cyclopeptides is realized, and the in-situ oxidation of an in-vivo tumor microenvironment is simulated for photo-thermal therapy and cell membrane coating. The method disclosed by the invention is simple, mild in experimental condition and easy to operate, the prepared cell membrane coated nano assembly not only has long circulation stability and high cell entry efficiency, but also can realize mild photo-thermal therapy through in-situ oxidation, releases manganese ions to activate a CGAS-STING pathway for immunotherapy of tumors, and has a wide application prospect. The potential application value is realized in the field of combined treatment of tumors.

A specific antibody and an antigen binding fragment thereof against a CD228 protein, used for testing and treating multiple tumors, such as melanoma, mesothelioma, and colorectal cancer. An antibody binding fragment facilitates the diagnosis and treatment of cancer by specifically binding to CD228. The present invention further comprises antibody-drug conjugates (ADCs) in which drugs bind to antibodies by means of linkers, aiming to improve the treatment effect and reduce the impact on normal cells. Additionally, the present invention provides a nucleic acid encoding an antibody or an antigen binding fragment thereof, so as to produce a recombinant antibody or fragment. In addition, the present invention further provides a kit, used for laboratory research, clinical diagnosis and treatment effect monitoring, facilitating determination of whether tissues or cells express CD228, providing a new strategy for personalized and accurate treatment of cancer.

Provided herein are compounds that modulate the activity of melanoma inhibitor of apoptosis (ML-IAP) protein, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds.

The invention discloses an application of a polysaccharide monomer separated from schisandra chinensis in preparation of a PD-L1 + TAMs activator. A large number of experiments show that the polysaccharide monomer schisanan B separated from schisandra chinensis can effectively activate PD-L1 + TAMs cell subsets, so that the phagocytosis of TAMs is enhanced, and the proliferation of tumor cells is inhibited; therefore, it is determined that the polysaccharide monomer schisanan B separated from schisandra chinensis can serve as a natural PD-L1 + TAMs cell subset activator to be used for treating cancers such as non-small cell lung cancer, intestinal cancer, melanoma, urothelial carcinoma or liver cancer, and the polysaccharide monomer schisanan B has the advantages of being free of toxic and side effects, low in price, wide in adaptive patient population and the like.

A bispecific antibody construct comprising a first human binding domain which binds to human CDH19 on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell. A nucleic acid comprising a polynucleotide encoding the antibody construct, a vector comprising the nucleic acid comprising the polynucleotide and a host cell transformed or transfected with the nucleic acid comprising the polynucleotide or vector. A process for the production of the antibody construct, a medical use of the antibody construct in the treatment of melanoma, and a kit comprising the antibody construct.

The invention provides a microneedle preparation for co-delivering photo-thermal nano-enzyme and elemene as well as a preparation method and application of the microneedle preparation. The preparation method comprises the following steps: firstly, preparing a novel photo-thermal nano enzyme Au (at) MoS2 through a two-step water phase synthesis strategy; benefited from the synergistic effect of the hybrid material, the nano-enzyme shows significantly enhanced near-infrared (NIR) photothermal effect, peroxidase-like (POD) activity and glutathione-like peroxidase (GSHOx) activity, and can effectively remodel the tumor microenvironment and destroy the redox steady state. Furthermore, photo-thermal nano enzyme, beta-ELE and hyaluronic acid are used as raw materials, and a novel soluble microneedle preparation is successfully prepared through a template method. The novel composite microneedle is in a sharp rectangular pyramid shape, growth of melanoma can be effectively inhibited through percutaneous delivery of photo-thermal nano-enzyme and beta-ELE, remarkable systemic toxicity is avoided, and an innovative strategy is provided for non-invasive, efficient and safe melanoma combined treatment.

Immunogenic targets associated with one or more types of cancer, wherein the immunogenic target includes a shared splicing amino acid-based neoantigen present in any of SEQ ID NOs: 1-2545, or a nucleotide coding therefor, are described, as well as uses thereof, and methods of identifying such immunogenic targets. Particular embodiments relate to immunotherapies for treating a type of cancer, and methods of treating a type of cancer by administering such immunotherapies, wherein the immunotherapy includes an immunogenic target including a shared splicing amino acid-based neoantigen present in any of SEQ ID NOs: 1-2545, or a nucleotide coding therefor.

The present invention relates to a hetero (aromatic) ring-substituted cyclic diamine compound, the preparation thereof and the use thereof in the preparation of a drug for treating and / or preventing tumors. The structural formula of the compound is as shown in (I). The compound has a significant inhibitory effect on the growth of cells of tumors such as leukemia, lymphoma, breast cancer, melanoma, ovarian cancer, colorectal cancer, cervical cancer, lung cancer, prostate cancer, esophageal cancer, glioma, kidney cancer, nasopharyngeal carcinoma, liver cancer, gastric cancer and pancreatic cancer. Compared with the prior art, the compound of the present invention has a broad-spectrum anti-tumor activity, has a good effect on inhibiting tumors, and has an effect of degrading PD-L1 proteins, and is thus a PD-L1 immunomodulator.

The invention discloses an application of the number of neutrophils in predicting the curative effect of oncolytic viruses in treating tumors. In the application, the neutrophile granulocyte number level in the blood of a tumor patient is closely associated with the tumor treatment effect, and the applicable tumor syndromes are common, including melanoma, colorectal cancer, esophageal cancer, head and neck tumors, gastric cancer, biliary tract system tumors, sarcoma and other tumors. In the application, the critical value of the number of neutrophils for predicting the tumor treatment effect is 2 * 10 < 9 >-5.5 * 10 < 9 > / L, and the most preferable critical value is 4.0 * 10 < 9 > / L; the curative effect of OH2 single-drug treatment on tumor patients with the neutrophil number level below a critical value is better than that of tumor patients with the neutrophil number level above the critical value.

The invention provides a preparation method of collagen and an application of the collagen in anti-aging. According to the invention, the anti-aging antioxidant collagen peptide F-5-B is obtained through enzymolysis and column separation identification. It is identified that the polypeptide has good DPPH free radical scavenging capacity, ABTS free radical scavenging capacity and lipid peroxidation reaction inhibiting capacity, the collagen peptide F-5-B can further inhibit melanoma cells from synthesizing melanin, and the polypeptide can further obviously increase the SOD level in the liver of a mouse. SOD can help the body resist attack of free radicals, so that the aging process is slowed down. Therefore, the anti-aging pharmaceutical composition prepared from the polypeptide has a relatively good application prospect.

The invention discloses nano-engineered microalgae for photoimmunotherapy of melanoma and a preparation method of the nano-engineered microalgae. The preparation method comprises the following steps: S1, respectively putting tannic acid, potassium carbonate, sodium citrate and HAuCl4. 3H2O into water to prepare a tannic acid solution with the concentration of 4.3 mg / mL, a potassium carbonate solution with the concentration of 20.7 mg / mL, a sodium citrate reduction solution with the concentration of 0.7 mg / mL and a HAuCl4 solution with the concentration of 10.0 mg / mL; s2, dissolving a tannic acid solution and a potassium carbonate solution in the sodium citrate reduction solution to obtain a mixed solution; s3, the mixed solution is heated under stirring, a HAuCl4 solution is dropwise added, stirring continues, and AuNP is obtained; and S4, mixing the AuNP obtained in the step S3 with the microalgae PCC 7942, standing, incubating, and centrifugally washing, so as to obtain the nano-engineered microalgae PCC-coated AuNP. The functionalized microalgae drug delivery system (PCC-coated AuNP) prepared by the invention has the performance of respectively generating O2 and H2 through photosynthesis and photocatalytic reaction under the irradiation of 635 nm red light.

Disclosed in the present disclosure are an inhibitor against CTGF RNA, MITF RNA and SRD5A2 RNA and the use of the inhibitor. The inhibitor is a gene editing system. The gene editing system of the present disclosure is capable of knocking down CTGF RNA, MITF RNA and SRD5A2 RNA, and can be used for repairing scars, whitening skin, reducing or eliminating chloasma, preventing or treating melanoma, and / or preventing or treating androgenetic alopecia.

The invention discloses a novel polypeptide, a polypeptide derivative and application thereof, and belongs to the technical field of biological medicine. The invention specifically relates to a specific sequence, a discovery process, a specific anti-tumor type, a long-acting modification mode and application of the novel polypeptide. The tumors comprise one or more of brain glioma, neuroblastoma, head and neck cancer, esophagus cancer, thyroid cancer, lung cancer, liver cancer, kidney cancer, breast cancer, cervical cancer, uterine cancer, ovarian cancer, colon cancer, small intestinal cancer, ileocecum cancer, stomach cancer, bladder cancer, pancreatic cancer, prostate cancer, bile duct cancer, melanoma, sarcoma, myeloma, lymphoma and leukemia; the compound has the specific effect of inhibiting proliferation and / or metastasis of tumor cells, is wide in treatment spectrum and has important treatment value in various tumors.

The invention belongs to the technical field of medicinal chemistry, and particularly relates to a 3-sulfamoyl benzamide compound as well as a preparation method and application thereof. The 3-sulfamoyl benzamide compound has a structure as shown in a formula I. In the formula I, X is chlorine or trifluoromethyl; r1 and R2 are independently C1-4 alkyl or R1, R2 and N atoms connected with R1 and R2 jointly form a heterocyclic group, and the heterocyclic group is a substituted or unsubstituted five-membered or six-membered heterocyclic group; and when the heterocyclic group is a substituted heterocyclic group, the substituent group in the substituted heterocyclic group is one or more of C1-4 alkyl, phenyl and acetyl. The 3-sulfamoyl benzamide compound disclosed by the invention has a remarkable proliferation inhibition effect on HCT116 colon cancer cells, HeLa human cervical cancer cells, MDA-MB-231 human breast cancer cells and A375 human malignant melanoma cells.

The invention belongs to the field of biological pharmacy, and provides keratin YK93-4, a coding nucleic acid molecule thereof, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or genome integrated with the nucleic acid molecule, and a preparation method and a pharmaceutical composition of the keratin YK93-4. The invention also provides application of the keratin YK93-4 and related products thereof in preparation of medicines for treating lung cancer, lymphoma, breast cancer, melanoma, hysteromyoma, benign prostatic hyperplasia and the like.

There are disclosed inter alia polypeptides and nucleic acids encoding said polypeptides which are useful in the treatment, prevention and diagnosis of cancer, particularly ovarian cancer, osteosarcoma, colon cancer, breast cancer, skin cancer, melanoma, esophageal cancer, esophageal adenocarcinoma (EAC) and esophageal squamous cell carcinoma (ESSC), particularly esophageal cancer, or EAC or ESSC.

The embodiment of the invention provides a melanoma postoperative wound intelligent dressing, and belongs to the technical field of intelligent medical treatment. The intelligent dressing for the wound after the melanoma operation comprises a multiple monitoring module, an intelligent processing module and an on-demand drug delivery module which are arranged on a dressing base body, the multiple monitoring module is used for acquiring biological signals of a wound surface microenvironment in real time; and the intelligent processing unit analyzes the biological signal to generate a wound state judgment result, and controls the on-demand drug delivery module to trigger electrical stimulation or thermal stimulation based on the wound state judgment result so as to realize on-demand drug release. According to the scheme, the deep learning intelligent early warning model fusing the generative adversarial network and the Transform structure is constructed, high-precision analysis and dynamic risk judgment of melanoma postoperative wound multi-dimensional time sequence data are achieved, and the accuracy and stability of wound state recognition are effectively improved.

This invention belongs to the field of biopharmaceuticals and provides a keratin YK93-6, its encoding nucleic acid molecule, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or whose genome integrates the nucleic acid molecule, as well as a preparation method and a pharmaceutical composition thereof. It also provides the application of the above-mentioned keratin YK93-6 and other products in the preparation of drugs for treating benign prostatic hyperplasia, lymphoma, melanoma, analgesia, lactation, breast cancer, lung cancer, uterine fibroids, coagulation, etc.

The invention belongs to the technical field of drug system delivery, and particularly relates to a radiotherapy sensitization microneedle and application thereof. The invention relates to a design of a mitochondrial targeting photosensitive microneedle system and an application of the mitochondrial targeting photosensitive microneedle system in melanoma radiosensitization radiotherapy. According to the invention, an intelligent delivery platform of the microneedles (MNs) is fused with mitochondrial targeted photodynamic therapy, and a new normal form is developed for radiosensitization therapy of melanoma. According to the invention, a soluble hyaluronic acid (HA) microneedle array is adopted, and a mitochondrial targeting photosensitizer is loaded. After penetrating through the cuticle, the microneedle is rapidly dissolved in the corium layer, the photosensitizer is released, and mitochondrial targeted enrichment is achieved. Then, under the condition of 660 nm illumination, the photosensitizer generates active oxygen in a mitochondrial matrix to directly destroy the mitochondrial structure and function, so that the mitochondrial ROS storm is induced, and the tumor radiotherapy sensitivity is improved.

The invention belongs to the field of biological pharmacy, and provides keratin YK93-5, a coding nucleic acid molecule thereof, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or genome integrated with the nucleic acid molecule, and a preparation method and a pharmaceutical composition of the keratin YK93-5. The invention also provides application of the keratin YK93-5 and other products in preparation of drugs for treating lung cancer, lymphoma, breast cancer, melanoma, hysteromyoma, prostatic hyperplasia and the like.

The invention discloses an ultrasonic controllable multifunctional microneedle patch as well as a preparation method and application thereof, and belongs to the technical field of biological materials. The preparation method comprises the following steps: preparing crystalline CoW-LDH nanosheets from Co (NO3) 2.6 H2O, Na2WO4. 2H2O and NaOH, dispersing the crystalline CoW-LDH nanosheets in PBS (Phosphate Buffer Solution), centrifuging and collecting the crystalline CoW-LDH nanosheets, and re-dispersing the crystalline CoW-LDH nanosheets in ultrapure water to obtain amorphous CoW-LDH nanosheets; adding PEG (Polyethylene Glycol), ultrasonically dispersing, stirring at room temperature, centrifuging, collecting and centrifugally washing with ultrapure water to obtain a PEG modified amorphous CoW-LDH nanosheet; and adding microalgae and an amorphous CoW-LDH nanosheet modified by PEG (Polyethylene Glycol) to prepare the ultrasonic controllable multifunctional microneedle patch. The multifunctional microneedle patch disclosed by the invention is high in biological safety, can realize ultrasonic controllability, has a sonodynamic treatment effect and an oxygen supply effect, remarkably inhibits melanoma recurrence and remarkably promotes wound healing, and has a wide application prospect.

The invention relates to a marker combination for predicting curative effect of melanoma anti-PD-1 immunotherapy and application of the marker combination. Specifically, more abundant and more accurate biomarkers (S100, CD68, CD3, CD20, PD-L1 and PD-1) related to the curative effect of the melanoma immunotherapy are obtained through co-localization of a plurality of biomarkers and spatial feature analysis, and a prediction model for evaluating the curative effect of the melanoma anti-PD-1 immunotherapy is prepared by using the biomarkers. The model has good sensitivity and specificity, and has a wide application prospect.

The invention relates to a DDPM-based melanoma intelligent segmentation method and system. The method comprises the following steps of obtaining a dermatoscope image of melanoma and performing image preprocessing; inputting the dermatoscope image of the melanoma after image preprocessing into a DDPM segmentation model, gradually adding noise through a forward denoising process, gradually removing noise through a backward denoising process, further learning probability distribution of the dermatoscope image of the melanoma, and obtaining a segmentation result of the melanoma; the DDPM segmentation model comprises an encoder and a decoder, the encoder comprises a multi-scale feature fusion module and a double-attention module, and the encoder extracts multi-scale features of a dermatoscope image of the melanoma through a multi-scale convolutional layer; and the decoder gradually recovers the segmentation result of the dermatoscope image of the melanoma according to the multi-scale features of the dermatoscope image of the melanoma through up-sampling and feature fusion operations. Compared with the prior art, the method has the advantage that accurate segmentation of the melanoma image is realized.

Provided herein are methods for treating a disease or condition associated with one or more of: mtDNA fragmentation; cytostolic Ox-mtDNA; mtDNA release; or Casp1 activation and IL-1β production by administering an effective amount of an inhibitor of human flap endonuclease-1 (FEN1). These diseases include without limitation, an inflammatory or a neurodegenerative disease, such as Alzheimer's, disease, Parkinson's disease, atherosclerosis, NASH, asthma, inflammatory bowel disease, melanoma, metabolic pathologies, including obesity, type 2 diabetes, atherosclerosis, inflammatory bowel diseases, gout, and periodic fevers.

The invention provides a docetaxel-loaded platelet delivery system as well as a preparation method and application thereof, and relates to the technical field of medicines. According to the invention, the docetaxel-loaded platelet delivery system is obtained by loading the docetaxel with the platelets for the first time, so that the problem that in the prior art, the traditional docetaxel preparation (injection) needs to be solubilized by polysorbate 80, so that allergy is easily caused is avoided, the safety and biocompatibility of the docetaxel medicine are improved, and the docetaxel-loaded platelet delivery system is suitable for clinical application. And the docetaxel-loaded platelet delivery system has excellent stability and can be stored at normal temperature for a long time. The invention provides the preparation method of the docetaxel-loaded platelet delivery system, and the method is simple to operate, high in encapsulation efficiency and drug loading rate and suitable for popularization. The docetaxel-loaded platelet delivery system disclosed by the invention has an outstanding treatment effect on melanoma and has a good application prospect.

The invention relates to a hetero (aromatic) ring substituted cyclic diamine compound, preparation thereof and application of the hetero (aromatic) ring substituted cyclic diamine compound in preparation of drugs for treating and / or preventing tumors. The structural formula of the compound is shown as (I). The compound has an obvious growth inhibition effect on tumor cells of leukemia, lymphoma, breast cancer, melanoma, ovarian cancer, colorectal cancer, cervical cancer, lung cancer, prostate cancer, esophagus cancer, glioma, kidney cancer, nasopharynx cancer, liver cancer, stomach cancer, pancreatic cancer and the like. The compound disclosed by the invention has broad-spectrum anti-tumor activity; the compound has a good tumor inhibition effect and a PD-L1 protein degradation effect, and is a PD-L1 immunomodulator.

Chimeric antigen receptors for use in treating malignant melanoma and other cancers expressing CS1 are described.

The present invention relates to antigen binding proteins that specifically bind to a tumor expressed melanoma-associated antigen (MAGE) B2 antigenic peptide in a complex with MHC. The antigen binding proteins are provided for use in the treatment of MAGEB2- expressing cancers. Further provided are nucleic acids encoding the antigen binding proteins, vectors comprising the nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins.

The invention discloses an application of neomycin in preparation of a medicine for treating tumors, and experiments show that tumor growth can be significantly inhibited by inhibiting interference of LPS (Lipopolysaccharide) on an STING pathway. The invention further provides a pharmaceutical composition containing the neomycin and the STING agonist (such as diABZI, cGAMP or CMA), the neomycin and the STING agonist show a synergistic effect in tumor resistance, the composition can be used for preparing drugs for treating tumors such as melanoma and colon cancer, and it is indicated that the neomycin or the combination of the neomycin and the STING agonist has wide application prospects in the medical field.